Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 56 of 56 entries
Sorted by: Best Match Show Resources per page
Impact of intracoronary optical coherence tomography in routine clinical practice: A contemporary cohort study.

Cardiovascular revascularization medicine : including molecular interventions

Häner JD, Duband B, Ueki Y, Otsuka T, Combaret N, Siontis GCM, Bär S, Stortecky S, Motreff P, Losdat S, Windecker S, Souteyrand G, Räber L.
PMID: 34340915
Cardiovasc Revasc Med. 2021 Jul 27; doi: 10.1016/j.carrev.2021.07.024. Epub 2021 Jul 27.

BACKGROUND/PURPOSE: Guidelines recommend intracoronary optical coherence tomography (OCT) to assess stent failure and guide percutaneous coronary intervention (PCI) but OCT may be useful for other indications in routine clinical practice.METHODS/MATERIALS: We conducted an international registry of OCT cases at...

Cite
Häner JD, Duband B, Ueki Y, et al. Impact of intracoronary optical coherence tomography in routine clinical practice: A contemporary cohort study. Cardiovasc Revasc Med. 2021;doi: 10.1016/j.carrev.2021.07.024.
Häner, J. D., Duband, B., Ueki, Y., Otsuka, T., Combaret, N., Siontis, G. C. M., Bär, S., Stortecky, S., Motreff, P., Losdat, S., Windecker, S., Souteyrand, G., & Räber, L. (2021). Impact of intracoronary optical coherence tomography in routine clinical practice: A contemporary cohort study. Cardiovascular revascularization medicine : including molecular interventions, . https://doi.org/10.1016/j.carrev.2021.07.024
Häner, Jonas D, et al. "Impact of intracoronary optical coherence tomography in routine clinical practice: A contemporary cohort study." Cardiovascular revascularization medicine : including molecular interventions vol. (2021). doi: https://doi.org/10.1016/j.carrev.2021.07.024
Häner JD, Duband B, Ueki Y, Otsuka T, Combaret N, Siontis GCM, Bär S, Stortecky S, Motreff P, Losdat S, Windecker S, Souteyrand G, Räber L. Impact of intracoronary optical coherence tomography in routine clinical practice: A contemporary cohort study. Cardiovasc Revasc Med. 2021 Jul 27; doi: 10.1016/j.carrev.2021.07.024. Epub 2021 Jul 27. PMID: 34340915.
Copy Download .nbib Format: NLM
Oxygen uptake kinetics during treadmill walking in adolescents with clinically stable cystic fibrosis.

Physiotherapy theory and practice

Combret Y, Medrinal C, Prieur G, Robledo Quesada A, Gillot T, Gravier FE, Bonnevie T, Lamia B, Le Roux P, Reychler G.
PMID: 33390080
Physiother Theory Pract. 2021 Jan 04;1-9. doi: 10.1080/09593985.2020.1868029. Epub 2021 Jan 04.

No abstract available.

Cite
Combret Y, Medrinal C, Prieur G, et al. Oxygen uptake kinetics during treadmill walking in adolescents with clinically stable cystic fibrosis. Physiother Theory Pract. 2021;1-9doi: 10.1080/09593985.2020.1868029.
Combret, Y., Medrinal, C., Prieur, G., Robledo Quesada, A., Gillot, T., Gravier, F. E., Bonnevie, T., Lamia, B., Le Roux, P., & Reychler, G. (2021). Oxygen uptake kinetics during treadmill walking in adolescents with clinically stable cystic fibrosis. Physiotherapy theory and practice, 1-9. https://doi.org/10.1080/09593985.2020.1868029
Combret, Yann, et al. "Oxygen uptake kinetics during treadmill walking in adolescents with clinically stable cystic fibrosis." Physiotherapy theory and practice vol. (2021): 1-9. doi: https://doi.org/10.1080/09593985.2020.1868029
Combret Y, Medrinal C, Prieur G, Robledo Quesada A, Gillot T, Gravier FE, Bonnevie T, Lamia B, Le Roux P, Reychler G. Oxygen uptake kinetics during treadmill walking in adolescents with clinically stable cystic fibrosis. Physiother Theory Pract. 2021 Jan 04;1-9. doi: 10.1080/09593985.2020.1868029. Epub 2021 Jan 04. PMID: 33390080.
Copy Download .nbib Format: NLM
Prehabilitation sessions can be provided more frequently in a shortened regimen with similar or better efficacy in people with non-small cell lung cancer: a randomised trial.

Journal of physiotherapy

Gravier FE, Smondack P, Boujibar F, Prieur G, Medrinal C, Combret Y, Muir JF, Baste JM, Cuvelier A, Debeaumont D, Bonnevie T.
PMID: 34952813
J Physiother. 2022 Jan;68(1):43-50. doi: 10.1016/j.jphys.2021.12.010. Epub 2021 Dec 21.

QUESTION: In people with non-small cell lung cancer, what is the effect of condensing 15 prehabilitation sessions into a 3-week regimen compared with a 5-week regimen?DESIGN: Randomised controlled trial with concealed allocation, intention-to-treat analysis and blinded assessment of the...

Cite
Gravier FE, Smondack P, Boujibar F, et al. Prehabilitation sessions can be provided more frequently in a shortened regimen with similar or better efficacy in people with non-small cell lung cancer: a randomised trial. J Physiother. 2021;68(1):43-50doi: 10.1016/j.jphys.2021.12.010.
Gravier, F. E., Smondack, P., Boujibar, F., Prieur, G., Medrinal, C., Combret, Y., Muir, J. F., Baste, J. M., Cuvelier, A., Debeaumont, D., & Bonnevie, T. (2022). Prehabilitation sessions can be provided more frequently in a shortened regimen with similar or better efficacy in people with non-small cell lung cancer: a randomised trial. Journal of physiotherapy, 68(1), 43-50. https://doi.org/10.1016/j.jphys.2021.12.010
Gravier, Francis-Edouard, et al. "Prehabilitation sessions can be provided more frequently in a shortened regimen with similar or better efficacy in people with non-small cell lung cancer: a randomised trial." Journal of physiotherapy vol. 68,1 (2022): 43-50. doi: https://doi.org/10.1016/j.jphys.2021.12.010
Gravier FE, Smondack P, Boujibar F, Prieur G, Medrinal C, Combret Y, Muir JF, Baste JM, Cuvelier A, Debeaumont D, Bonnevie T. Prehabilitation sessions can be provided more frequently in a shortened regimen with similar or better efficacy in people with non-small cell lung cancer: a randomised trial. J Physiother. 2022 Jan;68(1):43-50. doi: 10.1016/j.jphys.2021.12.010. Epub 2021 Dec 21. PMID: 34952813.
Copy Download .nbib Format: NLM
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.

ESMO open

Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L.
PMID: 34864351
ESMO Open. 2021 Dec 01;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 01.

BACKGROUND: Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading to frequent drug discontinuations. Whereas an exposure/safety relationship was demonstrated for this drug, an...

Cite
Cerbone L, Combarel D, Geraud A, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6(6):100312doi: 10.1016/j.esmoop.2021.100312.
Cerbone, L., Combarel, D., Geraud, A., Auclin, E., Foulon, S., Alves Costa Silva, C., Colomba, E., Carril, L., Derosa, L., Flippot, R., Mir, O., Khoudour, N., Blanchet, B., Escudier, B., Paci, A., & Albiges, L. (2021). Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO open, 6(6), 100312. https://doi.org/10.1016/j.esmoop.2021.100312
Cerbone, L, et al. "Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study." ESMO open vol. 6,6 (2021): 100312. doi: https://doi.org/10.1016/j.esmoop.2021.100312
Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves Costa Silva C, Colomba E, Carril L, Derosa L, Flippot R, Mir O, Khoudour N, Blanchet B, Escudier B, Paci A, Albiges L. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021 Dec 01;6(6):100312. doi: 10.1016/j.esmoop.2021.100312. Epub 2021 Dec 01. PMID: 34864351; PMCID: PMC8645912.
Copy Download .nbib Format: NLM
Targeted Therapy of .

Clinical cancer research : an official journal of the American Association for Cancer Research

Chen J, Nelson C, Wong M, Tee AE, Liu PY, La T, Fletcher JI, Kamili A, Mayoh C, Bartenhagen C, Trahair TN, Xu N, Jayatilleke N, Wong M, Peng H, Atmadibrata B, Cheung BB, Lan Q, Bryan TM, Mestdagh P, Vandesompele J, Combaret V, Boeva V, Wang JY, Janoueix-Lerosey I, Cowley MJ, MacKenzie KL, Dolnikov A, Li J, Polly P, Marshall GM, Reddel RR, Norris MD, Haber M, Fischer M, Zhang XD, Pickett HA, Liu T.
PMID: 33310889
Clin Cancer Res. 2021 Mar 01;27(5):1438-1451. doi: 10.1158/1078-0432.CCR-20-3044. Epub 2020 Dec 11.

EXPERIMENTAL DESIGN: Anticancer agents exerting the best synergistic anticancer effects with BET bromodomain inhibitors were identified by screening an FDA-approved oncology drug library. The synergistic effects of the BET bromodomain inhibitor OTX015 and the proteasome inhibitor carfilzomib were examined...

Cite
Chen J, Nelson C, Wong M, et al. Targeted Therapy of . Clin Cancer Res. 2020;27(5):1438-1451doi: 10.1158/1078-0432.CCR-20-3044.
Chen, J., Nelson, C., Wong, M., Tee, A. E., Liu, P. Y., La, T., Fletcher, J. I., Kamili, A., Mayoh, C., Bartenhagen, C., Trahair, T. N., Xu, N., Jayatilleke, N., Wong, M., Peng, H., Atmadibrata, B., Cheung, B. B., Lan, Q., Bryan, T. M., Mestdagh, P., Vandesompele, J., Combaret, V., Boeva, V., Wang, J. Y., Janoueix-Lerosey, I., Cowley, M. J., MacKenzie, K. L., Dolnikov, A., Li, J., Polly, P., Marshall, G. M., Reddel, R. R., Norris, M. D., Haber, M., Fischer, M., Zhang, X. D., Pickett, H. A., & Liu, T. (2021). Targeted Therapy of . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1438-1451. https://doi.org/10.1158/1078-0432.CCR-20-3044
Chen, Jingwei, et al. "Targeted Therapy of ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,5 (2021): 1438-1451. doi: https://doi.org/10.1158/1078-0432.CCR-20-3044
Chen J, Nelson C, Wong M, Tee AE, Liu PY, La T, Fletcher JI, Kamili A, Mayoh C, Bartenhagen C, Trahair TN, Xu N, Jayatilleke N, Wong M, Peng H, Atmadibrata B, Cheung BB, Lan Q, Bryan TM, Mestdagh P, Vandesompele J, Combaret V, Boeva V, Wang JY, Janoueix-Lerosey I, Cowley MJ, MacKenzie KL, Dolnikov A, Li J, Polly P, Marshall GM, Reddel RR, Norris MD, Haber M, Fischer M, Zhang XD, Pickett HA, Liu T. Targeted Therapy of . Clin Cancer Res. 2021 Mar 01;27(5):1438-1451. doi: 10.1158/1078-0432.CCR-20-3044. Epub 2020 Dec 11. PMID: 33310889.
Copy Download .nbib Format: NLM
Frequency and Prognostic Impact of .

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G.
PMID: 34115544
J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11.

PURPOSE: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied MATERIALS AND METHODS: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine RESULTS: Genomic CONCLUSION:...

Cite
Bellini A, Pötschger U, Bernard V, et al. Frequency and Prognostic Impact of . J Clin Oncol. 2021;39(30):3377-3390doi: 10.1200/JCO.21.00086.
Bellini, A., Pötschger, U., Bernard, V., Lapouble, E., Baulande, S., Ambros, P. F., Auger, N., Beiske, K., Bernkopf, M., Betts, D. R., Bhalshankar, J., Bown, N., de Preter, K., Clément, N., Combaret, V., Font de Mora, J., George, S. L., Jiménez, I., Jeison, M., Marques, B., Martinsson, T., Mazzocco, K., Morini, M., Mühlethaler-Mottet, A., Noguera, R., Pierron, G., Rossing, M., Taschner-Mandl, S., Van Roy, N., Vicha, A., Chesler, L., Balwierz, W., Castel, V., Elliott, M., Kogner, P., Laureys, G., Luksch, R., Malis, J., Popovic-Beck, M., Ash, S., Delattre, O., Valteau-Couanet, D., Tweddle, D. A., Ladenstein, R., & Schleiermacher, G. (2021). Frequency and Prognostic Impact of . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(30), 3377-3390. https://doi.org/10.1200/JCO.21.00086
Bellini, Angela, et al. "Frequency and Prognostic Impact of ." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,30 (2021): 3377-3390. doi: https://doi.org/10.1200/JCO.21.00086
Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Frequency and Prognostic Impact of . J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11. PMID: 34115544.
Copy Download .nbib Format: NLM
[Contribution of optical coherence tomography in the management of intrastent restenosis].

Annales de cardiologie et d'angeiologie

Mouyen T, Combaret N, Souteyrand G.
PMID: 34756601
Ann Cardiol Angeiol (Paris). 2021 Dec;70(6):451-456. doi: 10.1016/j.ancard.2021.10.010. Epub 2021 Oct 29.

Intrastent restenosis (ISR) remains a common problem in interventional cardiology. Angiographic data are limited in assessing ISR. Optical coherence tomography (OCT) is a high-resolution endocoronary imaging technique. It allows individualization of the stent struts and thus reveals stent under-expansion...

Cite
Mouyen T, Combaret N, Souteyrand G. Apport de la tomographie par cohérence optique dans la prise en charge de la resténose intrastent. [Contribution of optical coherence tomography in the management of intrastent restenosis]. Ann Cardiol Angeiol (Paris). 2021;70(6):451-456doi: 10.1016/j.ancard.2021.10.010.
Mouyen, T., Combaret, N., & Souteyrand, G. (2021). Apport de la tomographie par cohérence optique dans la prise en charge de la resténose intrastent. [Contribution of optical coherence tomography in the management of intrastent restenosis]. Annales de cardiologie et d'angeiologie, 70(6), 451-456. https://doi.org/10.1016/j.ancard.2021.10.010
Mouyen, Thomas, et al. "Apport de la tomographie par cohérence optique dans la prise en charge de la resténose intrastent." [Contribution of optical coherence tomography in the management of intrastent restenosis]. Annales de cardiologie et d'angeiologie vol. 70,6 (2021): 451-456. doi: https://doi.org/10.1016/j.ancard.2021.10.010
Mouyen T, Combaret N, Souteyrand G. Apport de la tomographie par cohérence optique dans la prise en charge de la resténose intrastent. [Contribution of optical coherence tomography in the management of intrastent restenosis]. Ann Cardiol Angeiol (Paris). 2021 Dec;70(6):451-456. doi: 10.1016/j.ancard.2021.10.010. Epub 2021 Oct 29. French. PMID: 34756601.
Copy Download .nbib Format: NLM
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.

Cancers

Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, Besse B.
PMID: 33327482
Cancers (Basel). 2020 Dec 14;12(12). doi: 10.3390/cancers12123758.

Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene addiction. This study assesses KI plasma levels and their clinical relevance in patients chronically exposed to KIs....

Cite
Geraud A, Mezquita L, Auclin E, et al. Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123758.
Geraud, A., Mezquita, L., Auclin, E., Combarel, D., Delahousse, J., Gougis, P., Massard, C., Jovelet, C., Caramella, C., Adam, J., Naltet, C., Lavaud, P., Gazzah, A., Lacroix, L., Rouleau, E., Vasseur, D., Mir, O., Planchard, D., Paci, A., & Besse, B. (2020). Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers, 12(12), . https://doi.org/10.3390/cancers12123758
Geraud, Arthur, et al. "Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123758
Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, Besse B. Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers (Basel). 2020 Dec 14;12(12). doi: 10.3390/cancers12123758. PMID: 33327482; PMCID: PMC7764991.
Copy Download .nbib Format: NLM
Showing 49 to 56 of 56 entries